Skip to main content

Advertisement

SpringerLink
Log in

Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

To demonstrate the effect of zoledronic acid in proliferation, invasion, and migration of human nasopharyngeal carcinoma cell HNE-1 and explore the potential role of VEGF, MMP-2, and MMP-9 proteins in vitro. Human nasopharyngeal carcinoma cell HNE-1 was exposed to various concentrations (0–40 μmol/l) of zoledronic acid. Zoledronic acid inhibited proliferation of HNE-1 cells though not in a dose-dependent manner. Zoledronic acid had exerted a dose-dependent effect on the migration and invasion of HNE-1 cells. Both expressions of mRNA and protein of MMP2, MMP9, and VEGF were reduced, respectively, detected by RT-PCR and Western blot assays. These data suggested that zoledronic acid not only inhibited growth but also invasion and migration of HNE-1 cells in vitro. The anti-cancer action of zoledronic acid was partially associated with the suppression of VEGF expression and secretion and downregulating the expression of MMP2 and MMP9.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Mcderrmott AL, Dutt SN, Watkinson JC. The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci. 2001;26:82–92.

    Article  Google Scholar 

  2. Arango BA, Castrellon AB, Perez CA, Raez LE, Santos ES. Nasopharyngeal carcinoma: alternative treatment options after disease progression. Expert Rev Anticancer Ther. 2010;10:377–86.

    Article  PubMed  Google Scholar 

  3. Caponigro F, Longo F, Ionna F, Perri F. Treatment approaches to nasopharyngeal carcinoma: a review. Anticancer Drugs. 2010;21:471–7.

    Article  PubMed  CAS  Google Scholar 

  4. Razak AR, et al. Nasopharyngeal carcinoma: the next challenges. Eur J Cancer. 2010;46:1967–78.

    Article  PubMed  Google Scholar 

  5. Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T. Zoledronic acid—a multiplicity of anti-cancer action. Curr Med Chem. 2007;14:2126–35.

    Article  PubMed  CAS  Google Scholar 

  6. Clézardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 2005;65:4971–4.

    Article  PubMed  Google Scholar 

  7. Winter MC, Holen I, Coleman RE. Exploring the anti-tumor activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008;34:453–75.

    Article  PubMed  CAS  Google Scholar 

  8. Gnant M, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679–91.

    Article  PubMed  CAS  Google Scholar 

  9. Rack B, et al. Effect of zoledronate on persisting isolated tumor cells in patients with early breast cancer. Anticancer Res. 2010;30:1807–13.

    PubMed  CAS  Google Scholar 

  10. Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer. 2003;88:1631–40.

    Article  PubMed  CAS  Google Scholar 

  11. Hasmim M, Bieler G, Rüegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost. 2007;5:166–73.

    Article  PubMed  CAS  Google Scholar 

  12. Goffinet M, et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer. 2006;6:60.

    Article  PubMed  CAS  Google Scholar 

  13. Boissier S, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60:2949–54.

    PubMed  CAS  Google Scholar 

  14. Ferretti G, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology. 2005;69:35–43.

    Article  PubMed  CAS  Google Scholar 

  15. Santini D, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007;13:4482–6.

    Article  PubMed  CAS  Google Scholar 

  16. Facchini G, et al. Metronomic administration of zoledronic acid, taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther. 2010;10:6.

    Google Scholar 

  17. Aft R, et al. Effect of zoledronic acid on disseminated tumor cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010;11:421–8.

    Article  PubMed  CAS  Google Scholar 

  18. Ottewell PD, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res. 2008;14:4658–66.

    Article  PubMed  CAS  Google Scholar 

  19. Fabbri F, et al. Zoledronic acid increases docetaxel cytotoxicity through pMEK, Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med. 2008;6:43.

    Article  PubMed  Google Scholar 

  20. Giraudo E, Hanahan D. Zoledronia acid inhibit angiogenesis and impairs tumorigenesis in a mouse model of cervical carcinogenesis. Haematol Rep. 2006;2:39–41.

    Google Scholar 

  21. Bäckman U, Svensson A, Christofferson RH, Azarbayjani F. The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res. 2008;28:1551–7.

    PubMed  Google Scholar 

  22. Soltau J, et al. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res. 2008;28:933–41.

    PubMed  CAS  Google Scholar 

  23. Li YY, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer. 2008;59:180–91.

    Article  PubMed  Google Scholar 

  24. Karabulut B, et al. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int. 2009;33:239–46.

    Article  PubMed  CAS  Google Scholar 

  25. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67.

    Article  PubMed  CAS  Google Scholar 

  26. Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life. 2001;52:61–6.

    Article  PubMed  CAS  Google Scholar 

  27. Evans KD, Oberbauer AM. Alendronate inhibits VEGF expression in growth plate chondrocytes by acting on the mevalonate pathway. Open Orthop J. 2009;3:83–8.

    Article  PubMed  CAS  Google Scholar 

  28. Santini D, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007;13:4482–6.

    Article  PubMed  CAS  Google Scholar 

  29. Montague R, et al. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of zoledronic acid in prostate cancer. Eur Urol. 2004;46:389–402.

    Article  PubMed  CAS  Google Scholar 

  30. Li YY, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer. 2008;59:180–91.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Cancer Hospital of Shantou University Medical College, 7 Raoping Road, Shantou, 515031, China

    Xu-yuan Li, Ying-cheng Lin, Wan-lan Huang & Wei-bing Li

  2. Department of Laboratory, Cancer Hospital of Shantou University Medical College, Shantou, 515031, China

    Chao-qun Hong, Jiong-yu Chen & Yan-jie You

Authors
  1. Xu-yuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ying-cheng Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wan-lan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chao-qun Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiong-yu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yan-jie You
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei-bing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ying-cheng Lin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, Xy., Lin, Yc., Huang, Wl. et al. Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells. Med Oncol 29, 714–720 (2012). https://doi.org/10.1007/s12032-011-9904-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-9904-1

Keywords

Search

Navigation